CA3021681C - USE OF BETA-AGONISTS OF THYROID HORMONES - Google Patents
USE OF BETA-AGONISTS OF THYROID HORMONESInfo
- Publication number
- CA3021681C CA3021681C CA3021681A CA3021681A CA3021681C CA 3021681 C CA3021681 C CA 3021681C CA 3021681 A CA3021681 A CA 3021681A CA 3021681 A CA3021681 A CA 3021681A CA 3021681 C CA3021681 C CA 3021681C
- Authority
- CA
- Canada
- Prior art keywords
- group
- alkyl
- compound
- receptor beta
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326436P | 2016-04-22 | 2016-04-22 | |
| US62/326,436 | 2016-04-22 | ||
| PCT/US2017/029120 WO2017185087A1 (en) | 2016-04-22 | 2017-04-24 | Use of thyroid beta-agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3021681A1 CA3021681A1 (en) | 2017-10-26 |
| CA3021681C true CA3021681C (en) | 2024-09-24 |
Family
ID=60116400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3021681A Active CA3021681C (en) | 2016-04-22 | 2017-04-24 | USE OF BETA-AGONISTS OF THYROID HORMONES |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11351183B2 (enExample) |
| EP (1) | EP3445373B1 (enExample) |
| JP (1) | JP6931042B2 (enExample) |
| KR (1) | KR102407059B1 (enExample) |
| AU (1) | AU2017252126B2 (enExample) |
| BR (1) | BR112018071586A2 (enExample) |
| CA (1) | CA3021681C (enExample) |
| ES (1) | ES2992773T3 (enExample) |
| MX (1) | MX385085B (enExample) |
| WO (1) | WO2017185087A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2992773T3 (en) | 2016-04-22 | 2024-12-18 | Viking Therapeutics Inc | Use of thyroid beta-agonists |
| EP3768690B1 (en) * | 2018-03-22 | 2025-08-27 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| JP2007524656A (ja) | 2003-10-23 | 2007-08-30 | セルジーン・コーポレーション | 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法 |
| EP1689383B1 (en) | 2003-11-19 | 2012-10-31 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| NZ561148A (en) | 2004-12-08 | 2008-12-24 | Sirion Therapeutics Inc | Methods, assays and compositions for treating retinol-related diseases |
| CA2606498C (en) * | 2005-05-26 | 2016-08-09 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| EP1898926A2 (en) | 2005-05-26 | 2008-03-19 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| US20090042857A1 (en) | 2006-02-20 | 2009-02-12 | Masuo Yamaoka | Novel Pharmaceutical |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| CN107201364A (zh) | 2011-06-21 | 2017-09-26 | 阿尔尼拉姆医药品有限公司 | 用于抑制载脂蛋白c‑iii（apoc3）基因表达的组合物与方法 |
| WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| WO2016134292A1 (en) | 2015-02-20 | 2016-08-25 | Oregon Health & Science University | Derivatives of sobetirome |
| RU2719245C2 (ru) | 2016-02-29 | 2020-04-17 | Филип Моррис Продактс С.А. | Тара и заготовка с шарнирной крышкой |
| ES2992773T3 (en) | 2016-04-22 | 2024-12-18 | Viking Therapeutics Inc | Use of thyroid beta-agonists |
| AU2017252122B2 (en) | 2016-04-22 | 2023-02-09 | Viking Therapeutics, Inc. | Use of Thyroid beta-Agonists |
| CA3024680A1 (en) | 2016-05-18 | 2017-11-23 | Oregon Health & Science University | Derivatives of sobetirome |
-
2017
- 2017-04-24 ES ES17786798T patent/ES2992773T3/es active Active
- 2017-04-24 WO PCT/US2017/029120 patent/WO2017185087A1/en not_active Ceased
- 2017-04-24 CA CA3021681A patent/CA3021681C/en active Active
- 2017-04-24 US US16/095,228 patent/US11351183B2/en active Active
- 2017-04-24 MX MX2018012900A patent/MX385085B/es unknown
- 2017-04-24 AU AU2017252126A patent/AU2017252126B2/en active Active
- 2017-04-24 EP EP17786798.3A patent/EP3445373B1/en active Active
- 2017-04-24 JP JP2019507069A patent/JP6931042B2/ja active Active
- 2017-04-24 KR KR1020187033713A patent/KR102407059B1/ko active Active
- 2017-04-24 BR BR112018071586-7A patent/BR112018071586A2/pt not_active Application Discontinuation
-
2022
- 2022-05-06 US US17/738,621 patent/US11951114B2/en active Active
-
2024
- 2024-03-05 US US18/595,919 patent/US12440502B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3445373A4 (en) | 2019-12-18 |
| KR20190039027A (ko) | 2019-04-10 |
| US11351183B2 (en) | 2022-06-07 |
| US20190321379A1 (en) | 2019-10-24 |
| US11951114B2 (en) | 2024-04-09 |
| JP6931042B2 (ja) | 2021-09-01 |
| KR102407059B1 (ko) | 2022-06-10 |
| MX385085B (es) | 2025-03-14 |
| ES2992773T3 (en) | 2024-12-18 |
| WO2017185087A1 (en) | 2017-10-26 |
| US20220257618A1 (en) | 2022-08-18 |
| MX2018012900A (es) | 2019-07-01 |
| AU2017252126A1 (en) | 2018-11-08 |
| EP3445373B1 (en) | 2024-08-21 |
| BR112018071586A2 (pt) | 2019-02-12 |
| US12440502B2 (en) | 2025-10-14 |
| EP3445373A1 (en) | 2019-02-27 |
| US20250000880A1 (en) | 2025-01-02 |
| CA3021681A1 (en) | 2017-10-26 |
| AU2017252126B2 (en) | 2023-02-09 |
| JP2019515033A (ja) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023202321B2 (en) | Use of thyroid beta-agonists | |
| US12440502B2 (en) | Use of thyroid beta-agonists | |
| KR102220175B1 (ko) | 헤테로사이클릭 글루타미나아제 억제제 | |
| AU2015274361B2 (en) | Combination therapy with glutaminase inhibitors | |
| KR20190125432A (ko) | 글루타미나제 억제제를 사용하는 병용 요법 | |
| UA123700C2 (uk) | Композиції і способи інгібування активності аргінази | |
| US11382908B2 (en) | Compositions and methods for treating inflammatory bowel disease | |
| AU2016246521A1 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| HK40064933A (en) | Use of thyroid beta-agonists | |
| HK40013781A (en) | Use of thyroid beta-agonists | |
| HK40007271A (en) | Use of thyroid beta-agonists | |
| HK40013781B (zh) | 甲状腺β-激动剂的应用 | |
| WO2017127417A1 (en) | Phosphopantothenate compounds | |
| AU2016326397A1 (en) | Conjoint therapies with inhibitors of glucose production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |